Bret Jensen
Bret Jensen is the lead equities analyst with Investors Alley. He's the editor of their newsletters including The Growth Stock Advisor and Biotech Gems.
Bret Jensen's Latest Posts
Sell These 5 Stocks On The Verge Of Bankruptcy
These stocks have serious red flags and are ticking time bombs in your portfolio. Several companies from our 2014 and 2015 watchlists are already bankrupt or very close, and the companies profiled today are likely on the same track. Dump these losers immediately. Bankruptcy is a scary thing but a natural part of the economic […]
3 Biotech Stocks That Can Double Before The End Of 2016
And, that is no exaggeration, these three biotech stocks all have near-term catalysts right around the corner that will send their currently undervalued share prices soaring when positive. Grab shares today because the catalysts we’re targeting for growth start happening in September. One of the keys to investing in the small cap portion of the […]
4 Undervalued Growth Stocks Deserving Your Interest
Pick up your pen and paper and write down the names of these four stocks that right now trade for valuations too low for their potential growth. With most stocks tading for premiums right now, finding four growth stocks with attractive valuations to add to your portfolio is worth your attention. I have followed and […]
4 Stocks To Buy With The Spread Of Zika
The Zika virus has been all over the news recently. It obviously is a backdrop for the Summer Olympics given the host country Brazil is the epicenter for this recent outbreak. The President and Congress continue to duel it out on assigning funding to tackle the virus from spreading further than it already has in […]
Top 5 Favorite Stocks After Earnings
After reading through hundreds of earnings reports, Bret Jensen has selected his top five favorite stocks with the best prospects after second quarter earnings. If you’re looking for a short-list of a top-rated analysts’s favortie stocks, look no further. We have been in the heart of second quarter earnings season for a couple of weeks […]
7 Stocks To Buy In The Market’s Hottest Sectors
Invest in the momentum of these seven stocks spanning three different sectors that all have strong economic tailwinds lifting their revenues, profits, and stock prices higher. As the market continues to flirt with and reach new all-time highs, many sectors in the market seem primed to far outpace their peers. Sometimes being a good investor […]
4 Likely Biotech Takeover Targets To Buy
After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Bret Jensen shares four more likely takeover targets that should be on your watchlist. It was a good week for the Biotech Gems portfolio. Progenics Pharmaceuticals (NASDAQ: PGNX) leapt 25% in […]
3 Undervalued Stocks With Strong Upcoming Catalysts
If all goes well for these three stocks, in the next six months they could be worth over double the prices they currently trade for. Each stock has important, business-defining events that, if positive (and it’s likely they will be), would make their businesses significantly more valuable. I get dozens of questions every week on […]
4 Undervalued Stocks To Buy And 5 Overvalued Stocks To Sell
Now that we’re at the half point of 2016, Bret Jensen identifies the best and worst areas to put your money for the rest of the year. Plus Bret gives you his favorite stocks in each of those sectors along with five stocks facing significant headwinds. It is hard to believe we are already in […]
Buy These 5 Undervalued Biotech Stocks On Sale Today
One, two, or three years out, investors will probably look back on the entry points in these five stocks and wonder why they did not allocate more funds to them. With growing earnings and revenues and M&A heating up, these five stocks are screaming buys right now. I was out at the Money Show in […]
Buy These 3 Takeover Targets For 2016
In my last column, I spoke on how M&A chatter has been increasing in the small and mid-cap names within the biotech sector. The derailment of the huge $150 billion merger between Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) is leading many analysts to put forth a list of names these companies could target as they […]
